NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
July 25, 2023 16:01 ET
|
NewAmsterdam Pharma Company B.V.
-- Exceeded Target Enrollment; Expect to Randomize More Than 2,500 Patients -- -- Topline Results Expected in 2H 2024 – NAARDEN, The Netherlands and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) --...
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
June 06, 2023 16:01 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
February 06, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...